Tests ALN-SOD in adults with ALS caused by a SOD1 gene change
Tests the safety of ALN-SOD, given into the spinal fluid, in adults with SOD1-related ALS.
Plain-language title generated from the registry record
Registry title: First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
Key facts
- Where
- Edmonton, London, Montreal, and Toronto, CanadaSee the 4 sites
- Phase
- Phase 1/2
Where in Canada
- University of Alberta Hospital, Edmonton, Division of NeurologyEdmonton, CanadaTaking people
- University Hospital - London Health Sciences CentreLondon, CanadaTaking people
- Montreal Neurological Institute and HospitalMontreal, CanadaTaking people
- Sunnybrook Research InstituteToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Regeneron Pharmaceuticals
- Trial code
- NCT06351592EU 2023-510344-20-00
- Record updated
- 11 September 2026
- Original description
This study is researching an experimental drug called ALN-SOD (called "study drug"). This study is focused on people with Amyotrophic Lateral Sclerosis (ALS) caused by a change in a gene called the Superoxide Dismutase-1 (SOD1) gene. This type of ALS is known as "SOD1-ALS". This is the first time that ALN-SOD will be given to people.Read full original descriptionShow less
First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ALN-SOD in Participants With Amyotrophic Lateral Sclerosis and SOD1 Mutations
This study is researching an experimental drug called ALN-SOD (called "study drug"). This study is focused on people with Amyotrophic Lateral Sclerosis (ALS) caused by a change in a gene called the Superoxide Dismutase-1 (SOD1) gene. This type of ALS is known as "SOD1-ALS". This is the first time that ALN-SOD will be given to people.
The aim of the study is to see how safe and tolerable the study drug is.
The study is looking at several other research questions, including:
* The effect the study drug has on specific biomarkers, which are substances in the blood or in the fluid that surrounds the brain and spinal cord, known as Cerebrospinal Fluid (CSF) * How much study drug is in the blood and in the CSF, at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) * What effects the study drug has on ALS symptoms
Inclusion: Weakness attributable to ALS and a SOD1 variant that has been previously described as associated with ALS or is considered likely to cause ALS, as defined in the protocol; Slow Vital Capacity (SVC) ≥50% predicted value based on age, gender and height, measured in upright position; Body Mass Index (BMI) ≤35 kg/m2 at time of screening; If participants are taking riluzole or edaravone, they must be on a stable dose for at least 4 weeks prior to initial dosing visit and are expected to remain at that dose until the end of the study; Platelet count >50,000/microliter; Has normal blood pressure readings, as defined in the protocol.
Exclusion: Concurrent participation in another interventional clinical trial; Has received treatment with tofersen within 6 months prior to screening; NOTE: Other protocol defined inclusion / exclusion criteria apply; Has dementia, as assessed by the investigator; Has uncontrolled psychiatric disease, including psychosis, active or recent suicidal ideation, untreated major depression, in the past 30 days; Has a medical history of brain or spinal disease/injury that would interfere with the Lumbar Puncture (LP) process, CSF circulation or safety assessment, as defined in the protocol; Has had a tracheostomy; Presence of an implanted shunt for the drainage of CSF or an implanted Central Nervous System (CNS) catheter; Presents any concern to the study investigator that might confound the results of the study or poses an additional risk to the participant by their participation in the study; Was hospitalized (ie, >24 hours) for any reason other than ALS within 30 days of screening.